Exchange: NASDAQ·Updated 04:48 PM EDT
COLL logo

COLLCollegium Pharmaceutical Inc

$35.85
$0.31
(0.87%)
Today
Closed $35.85
$0.00
(0.00%)
After Hours
EarningsAug 6
Mkt Cap$1.15B
Vol301,579.00
News
all
press releases
Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
More News
4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues
COLL, IRWD, AMTB and DUK stand out as defensive stock picks as investors rotate from AI-driven tech amid the ongoing sell-off and seek safer sectors.
Zacks
New Strong Buy Stocks for July 6th
BBCP, KUBTY, ADM, COLL and W have been added to the Zacks Rank #1 (Strong Buy) List on July 6, 2026.
Zacks
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why
COLL gains momentum as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and revenue outlook.
Zacks
Bull of the Day: Neurocrine Biosciences (NBIX)
Neurocrine Biosciences (NBIX) has quietly become one of biotech's strongest earnings stories.
Zacks
Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks
Collegium Pharmaceutical (COLL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +23.94% and +7.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Earnings Preview: Collegium Pharmaceutical (COLL) Q1 Earnings Expected to Decline
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Collegium Pharmaceutical (COLL) to Release Quarterly Earnings on Thursday
Collegium Pharmaceutical (NASDAQ:COLL) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.